翰森制药(03692.HK)偶联物HS-20093获FDA突破性疗法认定

阿斯达克财经
07 Jan

翰森制药(03692.HK) 公布,GlaxoSmithKline“GSK”就GSK5764227(亦称HS-20093)获美国食品药品监督管理局“FDA”授予突破性疗法认定,此B7-H3靶向抗体药物偶联物正在评估用于治疗既往经二线及以上治疗进展的复发或难治性骨癌成人患者。

2023年12月,集团与GSK订立协议,据此GSK获授予全球独占许可以开发、生产及商业化HS-20093。(de/d)(港股报价延迟最少十五分钟。沽空资料截至 2025-01-07 16:25。)

AASTOCKS新闻

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10